Statement attributable to the Board of Directors of the American Association for Clinical Chemistry: Over the past year, the COVID-19 pandemic has tested the limits of the laboratory medicine community s ingenuity and endurance. However, even as we have faced unprecedented challenges during this outbreak, our Asian and Asian American colleagues have been facing another outbreak: a surge of directed hostility and violence, fueled in part by xenophobic rhetoric around the coronavirus. It shouldn t have taken a shocking and deadly event to bring these circumstances to the level of attention and concern they have always deserved. We are appalled and angered by the horrific acts committed in and around Atlanta on March 16, which took the lives of eight people, including six Asian American women. We extend our deepest condolences to the families of all the shooting victims. We are equally devastated by the ongoing racist attacks targeting the Asian American community that preceded the
Share this article
Share this article
LEAWOOD, Kan., March 16, 2021 /PRNewswire/ ValueHealth, LLC, the nationally recognized leader in Ambulatory Centers of Excellence (ACE) TM has expanded its surgical ACE footprint to include Cleveland-based University Hospitals (UH), one of the nation s leading health systems. They today announced the first in a series of projects that will be developed through their new joint venture.
(PRNewsfoto/ValueHealth, LLC)
A new, state-of-the-art ambulatory surgery center in Lorain County, Ohio will focus on orthopedic surgical procedures delivered using consumer-based models, with the capacity for 800 total joints cases per year. Powered by ValueHealth s payor-led, tech-enabled, data-driven digital surgical platform that includes patient steerage, payor bundles, and warranty contracts, the surgery center will feature four operating rooms and post-surgery recovery Stay Suites that use a proven recovery model to reduce risks for patient readmiss
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
Full year 2020 revenues of $5.4 million compared to $2.3 million in 2019
News provided by
Share this article
Share this article
REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results. Last year we achieved many important milestones and objectives that set the foundation for the growth of DSUVIA® in 2021 and beyond, despite the global pandemic, said Vince Angotti, Chief Executive Officer of AcelRx. Like many other companies in our space, COVID has had an impact on the pace of approvals and adoption of DSUVIA as formulary review meetings and elective surgeries have been postponed. However, with vaccine rollouts and elective
NEOMED, University Hospitals partner to bolster medical student training crainscleveland.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from crainscleveland.com Daily Mail and Mail on Sunday newspapers.
AACI survey finds many opportunities for cancer center networks to increase patient satisfaction, outcomes
The consolidation of medical services into large systems of care is a major driver of health care economics. For patients with cancer, that may open the door to expert knowledge, cutting-edge treatments like personalized genomics, and clinical trials.
In a survey of the status of care across cancer center networks, some of which reach deep into rural areas, the Association of American Cancer Institutes (AACI) has found that many opportunities exist for such networks to increase patient satisfaction and outcomes and decrease treatment delays and risks.